304 related articles for article (PubMed ID: 17513231)
1. [Ximelagatran cannot be an alternative to standard warfarin therapy in chronic atrial fibrillation/ antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
Cavuşoğlu Y
Anadolu Kardiyol Derg; 2007 Jun; 7(2):217-8; author reply 218-9. PubMed ID: 17513231
[No Abstract] [Full Text] [Related]
2. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
Tandoğan I
Anadolu Kardiyol Derg; 2007 Jun; 7(2):216; author reply 218-9. PubMed ID: 17513230
[No Abstract] [Full Text] [Related]
3. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
Kiraç FS
Anadolu Kardiyol Derg; 2007 Jun; 7(2):214-5; author reply 218-9. PubMed ID: 17513229
[No Abstract] [Full Text] [Related]
4. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
Selçuk H; Selçuk MT; Maden O
Anadolu Kardiyol Derg; 2007 Mar; 7(1):54-8. PubMed ID: 17347079
[TBL] [Abstract][Full Text] [Related]
5. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
Douketis JD; Arneklev K; Goldhaber SZ; Spandorfer J; Halperin F; Horrow J
Arch Intern Med; 2006 Apr; 166(8):853-9. PubMed ID: 16636210
[TBL] [Abstract][Full Text] [Related]
6. Ximelagatran for stroke prevention in atrial fibrillation.
Boos CJ; Lip GY
Expert Rev Cardiovasc Ther; 2005 Jul; 3(4):551-63. PubMed ID: 16076267
[TBL] [Abstract][Full Text] [Related]
7. New possibilities in anticoagulant management of atrial fibrillation.
Waldo AL
Rev Cardiovasc Med; 2004; 5 Suppl 5():S30-8. PubMed ID: 15619613
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of markers of heart failure in patients with atrial fibrillation and the effects of ximelagatran compared to warfarin on the incidence of morbid and fatal events: a report from the SPORTIF III and V trials.
Cleland JG; Shelton R; Nikitin N; Ford S; Frison L; Grind M
Eur J Heart Fail; 2007; 9(6-7):730-9. PubMed ID: 17360232
[TBL] [Abstract][Full Text] [Related]
9. Ximelagatran versus warfarin in the prevention of atrial fibrillation-related stroke: both sides of the story.
Testa L; Van Gaal W; Agostoni P; Abbate A; Trotta G; Biondi-Zoccai GG
Stroke; 2007 Jul; 38(7):e57. PubMed ID: 17510448
[No Abstract] [Full Text] [Related]
10. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation.
O'Brien CL; Gage BF
JAMA; 2005 Feb; 293(6):699-706. PubMed ID: 15701911
[TBL] [Abstract][Full Text] [Related]
11. Ximelagatran or warfarin in atrial fibrillation?
Epstein EF
Lancet; 2004 Feb; 363(9410):736; author reply 736. PubMed ID: 15001338
[No Abstract] [Full Text] [Related]
12. Ximelagatran or warfarin in atrial fibrillation?
Stöllberger C; Finsterer J
Lancet; 2004 Feb; 363(9410):734-5; author reply 736. PubMed ID: 15001336
[No Abstract] [Full Text] [Related]
13. Ximelagatran or warfarin in atrial fibrillation?
MacAllister R; Hingorani AD; Casas JP
Lancet; 2004 Feb; 363(9410):735-6; author reply 736. PubMed ID: 15001337
[No Abstract] [Full Text] [Related]
14. Stroke prevention in atrial fibrillation: anticoagulants and antithrombotics.
Ezekowitz MD
Am Heart Hosp J; 2004; 2(4 Suppl 1):31-5. PubMed ID: 15539973
[TBL] [Abstract][Full Text] [Related]
15. Ximelagatran or warfarin in atrial fibrillation?
Eikelboom J; Hankey G
Lancet; 2004 Feb; 363(9410):734; author reply 734, 736. PubMed ID: 15001334
[No Abstract] [Full Text] [Related]
16. Anticoagulation in atrial fibrillation.
Anderson M; Kirk M
Med Health R I; 2004 Apr; 87(4):98-100. PubMed ID: 15168633
[TBL] [Abstract][Full Text] [Related]
17. Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials.
Akins PT; Feldman HA; Zoble RG; Newman D; Spitzer SG; Diener HC; Albers GW
Stroke; 2007 Mar; 38(3):874-80. PubMed ID: 17255547
[TBL] [Abstract][Full Text] [Related]
18. Trials and tribulations of non-inferiority: the ximelagatran experience.
Kaul S; Diamond GA; Weintraub WS
J Am Coll Cardiol; 2005 Dec; 46(11):1986-95. PubMed ID: 16325029
[TBL] [Abstract][Full Text] [Related]
19. [New perspectives for anticoagulation in non-rheumatic atrial fibrillation: oral antithrombins].
Scardi S; Giansante C
Ital Heart J Suppl; 2004 Sep; 5(9):705-11. PubMed ID: 15568608
[TBL] [Abstract][Full Text] [Related]
20. Ximelagatran compared with warfarin for the prevention of systemic embolism and stroke. An imputed placebo analysis.
Berry C; Norrie J; McMurray JJ
Cardiovasc Drugs Ther; 2005 Mar; 19(2):149-51. PubMed ID: 16025234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
